NO20000774D0 - Mutanter og gram-negative mukøse bakterier, og anvendelse derav i vaksiner - Google Patents
Mutanter og gram-negative mukøse bakterier, og anvendelse derav i vaksinerInfo
- Publication number
- NO20000774D0 NO20000774D0 NO20000774A NO20000774A NO20000774D0 NO 20000774 D0 NO20000774 D0 NO 20000774D0 NO 20000774 A NO20000774 A NO 20000774A NO 20000774 A NO20000774 A NO 20000774A NO 20000774 D0 NO20000774 D0 NO 20000774D0
- Authority
- NO
- Norway
- Prior art keywords
- mutants
- bacteria
- meningitidis
- lps
- deficient
- Prior art date
Links
- 241000894006 Bacteria Species 0.000 title abstract 3
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 239000002158 endotoxin Substances 0.000 abstract 3
- 229920006008 lipopolysaccharide Polymers 0.000 abstract 3
- 241000588650 Neisseria meningitidis Species 0.000 abstract 2
- 230000002950 deficient Effects 0.000 abstract 2
- 101150041203 lpxA gene Proteins 0.000 abstract 2
- 239000012528 membrane Substances 0.000 abstract 2
- 101710164702 Major outer membrane protein Proteins 0.000 abstract 1
- 101710116435 Outer membrane protein Proteins 0.000 abstract 1
- 230000008436 biogenesis Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000003833 cell viability Effects 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 238000002955 isolation Methods 0.000 abstract 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/NL1997/000474 WO1999010497A1 (en) | 1997-08-21 | 1997-08-21 | Novel mutants of gram negative mucosal bacteria and application thereof in vaccines |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20000774D0 true NO20000774D0 (no) | 2000-02-17 |
| NO20000774L NO20000774L (no) | 2000-04-14 |
| NO326858B1 NO326858B1 (no) | 2009-03-02 |
Family
ID=19866207
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20000774A NO326858B1 (no) | 1997-08-21 | 2000-02-17 | Mutanter av gram-negative mukose bakterier som er i stand til a danne OMP og mangler LPS, og anvendelse derav i vaksiner |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7011836B1 (no) |
| EP (1) | EP0991761B1 (no) |
| JP (1) | JP2001514001A (no) |
| AT (1) | ATE384130T1 (no) |
| AU (1) | AU755462B2 (no) |
| CA (1) | CA2300854C (no) |
| DE (1) | DE69738472T2 (no) |
| DK (1) | DK0991761T3 (no) |
| ES (1) | ES2301181T3 (no) |
| NO (1) | NO326858B1 (no) |
| PT (1) | PT991761E (no) |
| WO (1) | WO1999010497A1 (no) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9918319D0 (en) * | 1999-08-03 | 1999-10-06 | Smithkline Beecham Biolog | Vaccine composition |
| EP1261717B1 (en) * | 2000-03-02 | 2008-05-07 | CP Kelco U.S., Inc. | Mutant bacterial strains of the genus sphingonomas deficient in production of polyhydroxybutyrate and a process of clarification of sphingans |
| GB0220194D0 (en) | 2002-08-30 | 2002-10-09 | Chiron Spa | Improved vesicles |
| WO2005030122A2 (en) * | 2003-08-13 | 2005-04-07 | Chiron Corporation | Inactivated host cell delivery of polynucleotides encoding immunogens |
| CA2550927A1 (en) * | 2003-12-23 | 2005-07-14 | Glaxosmithkline Biologicals S.A. | A gram negative bacterium with reduced lps level in the outer membrane and use thereof for treating gram negative bacterial infection |
| WO2006085910A2 (en) * | 2004-06-04 | 2006-08-17 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Endotoxin-free moraxella catarrhalis |
| GB0424092D0 (en) | 2004-10-29 | 2004-12-01 | Chiron Srl | Immunogenic bacterial vesicles with outer membrane proteins |
| HUE030981T2 (en) * | 2006-01-19 | 2017-06-28 | Res Corp Tech Inc | Viable Non-Toxic Gram-negative Bacteria |
| GB0700562D0 (en) | 2007-01-11 | 2007-02-21 | Novartis Vaccines & Diagnostic | Modified Saccharides |
| DK2200642T3 (da) | 2007-10-19 | 2012-07-16 | Novartis Ag | Meningococvaccinepræparater |
| CN102356089B (zh) | 2008-02-21 | 2014-02-19 | 诺华股份有限公司 | 脑膜炎球菌fHBP多肽 |
| BRPI0909037B8 (pt) | 2008-03-03 | 2021-05-25 | Irm Llc | compostos moduladores da atividade de tlr, e composição farmacêutica |
| JP2012512240A (ja) | 2008-12-17 | 2012-05-31 | ノバルティス アーゲー | ヘモグロビン受容体を含む髄膜炎菌ワクチン |
| EP2440245B1 (en) | 2009-06-10 | 2017-12-06 | GlaxoSmithKline Biologicals SA | Benzonaphthyridine-containing vaccines |
| CA2772104A1 (en) | 2009-08-27 | 2011-03-03 | Novartis Ag | Hybrid polypeptides including meningococcal fhbp sequences |
| EP2470205A1 (en) | 2009-08-27 | 2012-07-04 | Novartis AG | Adjuvant comprising aluminium, oligonucleotide and polycation |
| SG178954A1 (en) | 2009-09-02 | 2012-04-27 | Novartis Ag | Immunogenic compositions including tlr activity modulators |
| TWI445708B (zh) | 2009-09-02 | 2014-07-21 | Irm Llc | 作為ｔｌｒ活性調節劑之化合物及組合物 |
| EP2483390A2 (en) | 2009-09-30 | 2012-08-08 | Novartis AG | Expression of meningococcal fhbp polypeptides |
| BR112012010531A2 (pt) | 2009-10-27 | 2019-09-24 | Novartis Ag | "polipeptídeos de modificação meningocócica fhbp" |
| WO2011057148A1 (en) | 2009-11-05 | 2011-05-12 | Irm Llc | Compounds and compositions as tlr-7 activity modulators |
| MX339146B (es) | 2009-12-15 | 2016-05-13 | Novartis Ag | Suspension homogenea de compuestos inmunopotenciadores y usos de los mismos. |
| JP5977678B2 (ja) * | 2010-03-12 | 2016-08-24 | リサーチ コーポレーション テクノロジーズ インコーポレイテッド | Ｔｌｒ４／ｍｄ−２の外膜アゴニストを欠く生存可能なグラム陰性細菌 |
| JP2013522287A (ja) | 2010-03-18 | 2013-06-13 | ノバルティス アーゲー | 血清群ｂ髄膜炎菌のためのアジュバント添加ワクチン |
| EA023725B1 (ru) | 2010-03-23 | 2016-07-29 | Новартис Аг | Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний |
| BR112013005626B1 (pt) | 2010-09-10 | 2022-07-26 | Glaxosmithkline Biologicals Sa | Meningococo, processo para a preparação de uma cepa meningocócica, vesículas de membrana externa, composição farmacêutica imunogênica, e, uso de uma composição |
| US20150147356A1 (en) | 2011-05-12 | 2015-05-28 | Alan Kimura | Antipyretics to enhance tolerability of vesicle-based vaccines |
| BR112014019166A2 (pt) | 2012-02-02 | 2017-07-04 | Novartis Ag | promotores para expressão aumentada de proteína em meningococos |
| EP2892553A1 (en) | 2012-09-06 | 2015-07-15 | Novartis AG | Combination vaccines with serogroup b meningococcus and d/t/p |
| HUE052293T2 (hu) | 2014-02-28 | 2021-04-28 | Glaxosmithkline Biologicals Sa | Módosított fHbp meningococcus-polipeptidek |
| WO2019157003A1 (en) * | 2018-02-06 | 2019-08-15 | Evelo Biosciences, Inc. | Compositions and methods for treating cancer and immune disorders using veillonella bacteria |
| WO2019169181A1 (en) * | 2018-02-28 | 2019-09-06 | Evelo Biosciences, Inc. | Compositions and methods for treating cancer using lactobacillus salivarius |
| WO2019169168A1 (en) * | 2018-02-28 | 2019-09-06 | Evelo Biosciences, Inc. | Compositions and methods for treating cancer using agathobaculum |
| EP3799884A1 (en) * | 2019-10-01 | 2021-04-07 | GlaxoSmithKline Biologicals S.A. | Immunogenic compositions |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8912330D0 (en) * | 1989-05-30 | 1989-07-12 | Wellcome Found | Live vaccines |
| DE69423383T2 (de) | 1993-05-13 | 2000-08-24 | American Cyanamid Co | Herstellung und Verwendungen von LOS-verminderten Aussenmembran-Proteinen von Gram-negativen Kokken |
| US6887483B2 (en) * | 1995-12-01 | 2005-05-03 | University Of Iowa Research Foundation | Non-toxic mutants of pathogenic gram-negative bacteria |
| WO1997025061A1 (en) | 1996-01-09 | 1997-07-17 | Bristol-Myers Squibb Company | De-myristolated lipopolysaccharide of gram-negative bacteria |
-
1997
- 1997-08-21 ES ES97936881T patent/ES2301181T3/es not_active Expired - Lifetime
- 1997-08-21 CA CA2300854A patent/CA2300854C/en not_active Expired - Fee Related
- 1997-08-21 PT PT97936881T patent/PT991761E/pt unknown
- 1997-08-21 DE DE69738472T patent/DE69738472T2/de not_active Expired - Lifetime
- 1997-08-21 WO PCT/NL1997/000474 patent/WO1999010497A1/en active IP Right Grant
- 1997-08-21 US US09/486,073 patent/US7011836B1/en not_active Expired - Lifetime
- 1997-08-21 EP EP97936881A patent/EP0991761B1/en not_active Expired - Lifetime
- 1997-08-21 AU AU39540/97A patent/AU755462B2/en not_active Ceased
- 1997-08-21 AT AT97936881T patent/ATE384130T1/de active
- 1997-08-21 JP JP2000507805A patent/JP2001514001A/ja active Pending
- 1997-08-21 DK DK97936881T patent/DK0991761T3/da active
-
2000
- 2000-02-17 NO NO20000774A patent/NO326858B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| ES2301181T3 (es) | 2008-06-16 |
| US7011836B1 (en) | 2006-03-14 |
| WO1999010497A1 (en) | 1999-03-04 |
| DE69738472T2 (de) | 2009-01-02 |
| EP0991761A1 (en) | 2000-04-12 |
| NO20000774L (no) | 2000-04-14 |
| DK0991761T3 (da) | 2008-05-19 |
| CA2300854C (en) | 2011-04-05 |
| ATE384130T1 (de) | 2008-02-15 |
| JP2001514001A (ja) | 2001-09-11 |
| NO326858B1 (no) | 2009-03-02 |
| CA2300854A1 (en) | 1999-03-04 |
| AU755462B2 (en) | 2002-12-12 |
| EP0991761B1 (en) | 2008-01-16 |
| PT991761E (pt) | 2008-04-28 |
| AU3954097A (en) | 1999-03-16 |
| DE69738472D1 (de) | 2008-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20000774D0 (no) | Mutanter og gram-negative mukøse bakterier, og anvendelse derav i vaksiner | |
| Amano et al. | Deficiency of peptidoglycan and lipopolysaccharide components in Rickettsia tsutsugamushi | |
| Guymon et al. | Cell envelope alterations in antibiotic-sensitive and-resistant strains of Neisseria gonorrhoeae | |
| ATE319476T1 (de) | Neuartige nicht pyrogene bakterienstämme und ihre verwendung | |
| CY1113032T1 (el) | Ετερολογη εκφραση πρωτεϊνων νειssεrια | |
| DE69423383D1 (de) | Herstellung und Verwendungen von LOS-verminderten Aussenmembran-Proteinen von Gram-negativen Kokken | |
| AU7392296A (en) | Dendritic cell stimulatory factor | |
| HUP9901039A2 (hu) | Neisseria meningitidis B-csoportba tartozó külső-membrán-fehérjéjének (MB3) expressziója élesztőben, továbbá vakcinák | |
| Swanson | Studies on gonococcus infection. XVIII. 125I-labeled peptide mapping of the major protein of the gonococcal cell wall outer membrane | |
| NO20024571L (no) | Immunoterapeutiske fremgangsmåter og blandinger | |
| ATE130198T1 (de) | Herstellung eines virus und reinigung von virenüberzugsproteinen zur impfstoffverwendung. | |
| ES2059436T3 (es) | Proteina de la membrana exterior f de pseudomonas aeruginosa. | |
| DE69515340D1 (de) | Impfstoff gegen mycobakterielle infektionen | |
| Modolell et al. | The Adjuvant Activity of a Mycobacterial Water Soluble Adjuvant (WSA) in vitro: I. The Requirement of Macrophages | |
| Pugsley et al. | Comparison of colicins B-K260 and D-CA23: purification and characterization of the colicins and examination of colicin immunity in the producing strains | |
| DK0563256T3 (da) | Anvendelse af værtscelle-phospholipider til inhibering af bakteriekolonisering | |
| Shiigi et al. | Sera and the in Vitro Induction of Immune Responses: III. Adjuvant Obtained from Gliding Bacteria with Properties Distinct from Enteric Bacterial Lipopolysaccharide | |
| Koga et al. | Composition of major outer membrane proteins of Vibrio vulnificus isolates: effect of different growth media and iron deficiency | |
| Harding | Techniques for studying phagocytic processing of bacteria for class I or II MHC-restricted antigen recognition by T lymphocytes | |
| Osada et al. | A possible role of glycolipids in epithelial cell penetration by virulent Shigella flexneri 2a | |
| BRPI0100837B8 (pt) | sequência de dna que codifica a proteína externa de membrana antigênica e específica de salmonella typhi | |
| Meysick et al. | Growth of Trichomonas vaginalis in a serum-free McCoy cell culture system | |
| Kawaoka et al. | Identification of Yersinia enterocolitica O15 lipopolysaccharide as a rough antigen | |
| VARDAR-ÜNLÜ | A Comparison of Germ Tube Production by Candidaalbicans in Three Media | |
| SU1726514A1 (ru) | Штамм бактерий VIвRIо сноLеRае еLтоR INава - продуцент @ -амилазы |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |